Stay updated on SAGE-217 for Severe Depression Clinical Trial
Sign up to get notified when there's something new on the SAGE-217 for Severe Depression Clinical Trial page.

Latest updates to the SAGE-217 for Severe Depression Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe new design introduces a refreshed page layout with a redesigned header, color scheme, and reorganized sections. The underlying study information remains the same.SummaryDifference0.3%

- Check18 days agoNo Change Detected
- Check40 days agoChange DetectedThe page has been updated to include a government-status notice and a version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference0.7%

- Check47 days agoChange DetectedUpdate to version v3.1.0 with removal of several drug-related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and prior version v3.0.2, implying a shift away from those topics.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated to v3.0.2 from v3.0.1; the Back to Top link was removed.SummaryDifference0.0%

- Check69 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.0%

- Check76 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new drug information related to Zuranolone and topics like teen depression and drug safety. However, several previous terms and categories related to locations and specific drug classifications have been removed.SummaryDifference0.4%

Stay in the know with updates to SAGE-217 for Severe Depression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-217 for Severe Depression Clinical Trial page.